...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Eerily quiet....
and yet so much evidence that interest in epigenetics is heating up. To be clear this is pure speculation on my part but... I just wonder, I just wonder.... Happy 2016 everyone. Haven't been posting because I haven't got much to say right now. But am still long and strong. Here's hoping for a profitable year. tundup
New Message
Please login to post a reply